Latest Health It Sector News

Skin Elements Limited reports successful completion of key product evaluations and secures $2.5 million placement to fuel growth and commercialisation in 2026.

InteliCare Holdings reported a $834,000 operating cash outflow for Q3 2025 but bolstered its balance sheet with a $1.8 million capital raise, positioning itself to sustain operations over the coming quarters.

MedAdvisor Limited will have its trading suspension lifted on 10 October 2025 following the lodgement of its annual financial report, marking a key moment for investors.

NIB Holdings Limited has updated its dividend details, declaring a fully franked ordinary dividend of AUD 0.16 per share for the first half of FY2025 and revising the Dividend Reinvestment Plan price to AUD 7.5154.

Jatcorp Limited reported a $6.9 million net loss for FY25, hit by a trademark dispute in China that suspended key product sales. Despite setbacks, the company is accelerating new channel growth and product innovation to regain momentum.

Biome Australia has secured key distribution partnerships with Mecca and Go Vita, launching its Activated Probiotics range into premium beauty and health food channels across Australia.

McPherson’s Limited reported a 3.9% revenue decline to $139 million in FY25 amid a strategic shift to a pharmacy wholesaler model, posting a $15 million net loss but signaling moderate EBITDA growth ahead.

Credit Corp Group Limited has announced a fully franked ordinary dividend of AUD 0.36 per share for the six months ending June 2025, signaling steady returns for investors.

Pro Medicus Limited has entered a strategic financing arrangement with 4DMedical to accelerate the development and commercialization of cutting-edge lung function imaging software.

InteliCare Holdings reported a $564,000 operating cash outflow in Q4 2025 and has secured $1 million in additional funding to support ongoing operations despite a cash runway under one quarter.

Enlitic, Inc. has confirmed its commitment to achieving operational cashflow break-even by the end of 2025, alongside maintaining its revenue guidance of US$9-11 million for the calendar year.

IDT Australia has signed a memorandum with NASDAQ-listed Gelteq to establish a dedicated gel-based product manufacturing facility, marking a strategic expansion in pharmaceutical delivery technologies.